Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Working Capital Changes: 2012-2024

Historic Other Working Capital Changes for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$7.4 million.

  • Theravance Biopharma's Other Working Capital Changes fell 263.33% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 226.47%. This contributed to the annual value of -$7.4 million for FY2024, which is 198.04% down from last year.
  • Theravance Biopharma's Other Working Capital Changes amounted to -$7.4 million in FY2024, which was down 198.04% from $7.5 million recorded in FY2023.
  • Over the past 5 years, Theravance Biopharma's Other Working Capital Changes peaked at $7.5 million during FY2023, and registered a low of -$26.5 million during FY2020.
  • For the 3-year period, Theravance Biopharma's Other Working Capital Changes averaged around $1.3 million, with its median value being $3.8 million (2022).
  • In the last 5 years, Theravance Biopharma's Other Working Capital Changes spiked by 133.17% in 2022 and then plummeted by 198.04% in 2024.
  • Over the past 5 years, Theravance Biopharma's Other Working Capital Changes (Yearly) stood at -$26.5 million in 2020, then surged by 56.69% to -$11.5 million in 2021, then skyrocketed by 133.17% to $3.8 million in 2022, then soared by 98.50% to $7.5 million in 2023, then plummeted by 198.04% to -$7.4 million in 2024.